Flagship’s ProFound Signs Up To $35 Million Gates Foundation Pact For Preeclampsia Targets
Dr. Priya Nandakumar
Coverage
AI in Drug Discovery
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Latest
Autolomous CEO Argues AI Must Link Shared Failure Data In Cell And Gene Therapy, After Sarepta Safety Setback
Dr. Alex Morgan
AI-Centric Biotechs Draw Billion-Dollar Backing, Pressuring Biopharma To Move Risk Checks Upstream
Dr. Priya Nandakumar
QuantHealth Secures $45M to Revolutionize Clinical Trial Simulation With AI
Michael Torres
Most read
AI Data Becomes Sticking Point in Biopharma Dealmaking
Jonathan Blake
Elevance Health’s AI Agenda: Simplifying Member Experience, Supporting Providers, and Empowering Employees
Sophia Reynolds
Secretive AI Drug Hunter Xaira Enters the Dealmaking Arena
Dr. Priya Nandakumar
AI Can Accelerate Discovery — Development Still Decides What Advances
Jonathan Blake
More in this beat
Aug 1, 2026Grove AI’s Rapid Rise: From Startup to Acquisition, Transforming Clinical Trials with Voice Technology
The healthcare industry witnessed one of its fastest success stories as Grove AI, a startup focused on AI-powered voice agents for clinical trial recruitment, was acquired by Hippocratic AI just two years after its founding. This deep dive profiles the technology, strategy, and market forces that shaped Grove AI’s journey and examines the broader implications for digital health innovation.
Dr. Alex MorganJul 22, 2026AI Data Becomes Sticking Point in Biopharma Dealmaking
The rapid expansion of AI-driven drug discovery is accelerating the complexity of biopharma collaborations. As these partnerships multiply, legal and operational disputes related to data ownership and provenance are surfacing as central friction points, forcing both sides to reconsider deal structures and the future of therapeutic innovation.
Jonathan Blake
Jul 21, 2026How Should Clinical AI Be Paid For? 3 Takeaways
Despite the growing prominence of artificial intelligence in clinical medicine, existing payment models are proving inefficient and potentially costly. The Peterson Health Technology Institute’s recent study explores why current structures may stifle innovation or accelerate spending, laying out core recommendations for a more sustainable financing approach.
Sophia Reynolds
Jul 20, 2026Bristol Myers Squibb Claims Pharma's Largest NVIDIA AI Supercomputer Initiative
BMS becomes the third major drugmaker in less than a year to announce the construction of the 'largest' NVIDIA AI supercomputer in pharma, reflecting escalating competition and unprecedented digital infrastructure investment across the industry.
Emily Carter
Jul 9, 2026Biopharma R&D Needs 'Structural Redesign' to Maximize AI Impact, Says McKinsey
Biopharma’s embrace of artificial intelligence has been enthusiastic, but a new analysis counsels that next-generation AI-enabled drug discovery will remain limited unless companies redesign how their R&D units are organized and operate. This post explores the implications and requirements for transformative change in the industry.
Dr. Alex Morgan
Jul 8, 2026Healthcare and AI: Can Integration Succeed Without Restructuring Responsibility?
Artificial intelligence has demonstrated remarkable potential in healthcare, especially in environments where conditions are carefully controlled. However, the true test emerges not in laboratory settings, but in real-world clinical workflows—where integration brings up sometimes-troublesome questions about who bears responsibility, who has authority, and how accountability is maintained. As healthcare leaders and clinicians embrace AI, the dynamics of this relationship become a microcosm of wider tensions in health innovation—and demand careful analysis if integration is to benefit both practitioners and patients.
Sophia ReynoldsJul 8, 2026Secretive AI Drug Hunter Xaira Enters the Dealmaking Arena
The little-known AI biotech Xaira Therapeutics has long operated behind the curtain, backed by over a billion dollars in initial funding. Now, signs indicate that Xaira is shifting its strategy from secrecy to collaboration in a bid to validate an emerging drug pipeline—marking an intriguing inflection point both for the company and the wider industry. With enormous resources and an enigmatic approach, Xaira’s search for external partners raises broader questions about transparency, trust, and validation within the rapidly evolving field of AI-driven pharmaceutical innovation.
Dr. Priya Nandakumar
Jul 5, 2026AI in Mental Health: Why Clinicians Need to Be in the Room
While AI promises to revolutionize many aspects of healthcare, mental health professionals argue that certain skills—such as navigating patient discomfort, challenging assumptions, and asking deeper questions—remain uniquely human. Bridging the gap between technology and compassionate care is increasingly seen as essential in the evolving mental health landscape.
Daniel Cho
Jul 4, 2026What Happens When AI Stops Answering and Starts Handling Healthcare Tasks?
As static chatbots reach their limits, the emergence of agentic AI promises to fundamentally change how healthcare tasks are managed for patients and providers alike. This article examines the real-world opportunities and dilemmas that come with entrusting sensitive healthcare functions to autonomous AI agents.
Dr. Alex Morgan
Jul 1, 2026AI Powerhouse Anthropic Ventures into Drug Development: A Paradigm Shift for Biotech?
AI giant Anthropic, after achieving household-name status in technology, is making bold advances into drug development. This move signals a possible industry-wide transformation as tech behemoths join the AI drug discovery race.
Dr. Priya Nandakumar
Jun 30, 2026Anthropic Unveils Claude Science: A New Era for AI in Pharma and Research
With an explosion of interest in artificial intelligence applications for drug discovery and biomedical research, the official release of Claude Science by Anthropic marks a significant development for the life sciences industry. This new application, tailored for the unique needs of researchers and pharmaceutical professionals, optimizes emerging AI technology to fundamentally reshape how complex scientific problems are tackled.
Dr. Priya Nandakumar
Jun 29, 2026AI Pioneer Edison Scientific Teams Up with Population Health Partners to Launch New Biotechs
Edison Scientific, a leader in AI-driven science, and investment firm Population Health Partners are joining forces to develop new biotechs empowered by artificial intelligence. The partnership will harness the potential of AI agents for drug discovery and development, promising to reinvent how biotech startups are founded and scaled in a rapidly evolving scientific landscape.
Jonathan BlakeOther beats
Biopharmaceutical Industry
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Biotech Innovation
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Healthcare Investment
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Medical Technology
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
Regulatory & Policy
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.